eli lilly retatrutide lawsuit Novo Nordisk is suing over its GLP-1 ads, accusing the rival drugmaker of false advertising for claiming Lilly's Mounjaro and Zepbound outperform Novo's Ozempic and Wegovy. MORE BELOW ⬇️ Eli Lilly Sues to Block

Recently, medications known as GLP-1 agonists, including Ozempic, have become increasingly popular due to their ability to support meaningful weight loss, even among individuals without diabetes

At the end of the day, I would recommend that these medications be avoided for weight loss unless all other treatments have failed

[DOI] [PubMed] [Google Scholar] 94.Wrotek S., Sobociska J., Kozowski H.M., Pawlikowska M., Jdrzejewski T., Dzialuk A

But no other patients stopped taking the drug due to adverse events across any of the different dosing groups, Amgen Chief Medical Officer Paul Burton said during a conference earlier this month

Selenium: tracing another essential element of ferroptotic cell death

The rationale is that AOD 9604 preferentially targets adipose tissue, which might help shift the composition of weight loss more toward fat and away from lean mass